Efficacy and safety of a B-cell-driven rituximab regimen for the treatment of refractory idiopathic membranous nephropathy

Authors

Institutions

Publication Details

Journal
BMC Pharmacology and Toxicology
Published
2025-07-04
DOI
https://doi.org/10.1186/s40360-025-00954-8
Citations
1
Primary Topic
Renal Diseases and Glomerulopathies
Type
article
Field-Weighted Citation Impact
1.43
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy and safety of a B-cell-driven rituximab regimen for the treatment of refractory idiopathic membranous nephropathy

Kaiqi Guo, Xiaowei Li, Huimin Li, Xingcheng Xu et al.
1 citations
BMC Pharmacology and Toxicology
Renal Diseases and Glomerulopathies
1.43
article

Efficacy and safety of a B-cell-driven rituximab regimen for the treatment of refractory idiopathic membranous nephropathy

Kaiqi Guo, Xiaowei Li, Huimin Li, Xingcheng Xu, Huaxia Zhu, Lanlan Huang
article en
1 citations

Abstract

No abstract available for this paper.
BMC Pharmacology and ToxicologyVol. 26(1)
Fuyang Second People's Hospital (CN)
Good health and well-being
Openalex Percentile: Top 18%
Renal Diseases and Glomerulopathies
1.43
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Efficacy and safety of a B-cell-driven rituximab regimen for the treatment of refractory idiopathic membranous nephropathy — Kaiqi Guo, Xiaowei Li, et al. · BMC Pharmacology and Toxicology (2025) | TGRS Research Map | TGRS